MedTrace Logo

SMC Radiation Oncology SABR Cohort for Oligometastasis

NCT07121335 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-08-13

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.

The main questions it aims to answer are:

1. oncologic outcomes (progression-free survival, local failure rate),
2. patient-reported outcomes,
3. physician-assessed toxicity, and
4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.

Conditions

  • Stereotactic Body Radiation Therapy (SBRT)
  • Oligometastasis
  • Oligoprogression
  • ctDNA
  • Patient-Reported Outcomes (PRO)

Interventions

RADIATION

Stereotactic body radiotherapy (SBRT)

Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2027-12-31
Completion
2030-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07121335 on ClinicalTrials.gov